|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.92 HKD | -0.51% |
|
-5.56% | -1.65% |
| Jun. 05 | Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub | CI |
| May. 31 | Wuxi Biologics adds 69 projects in Jan-April, maintains expected revenue growth | RE |
Company Valuation: WuXi Biologics (Cayman) Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 318,490 | 223,690 | 113,457 | 67,752 | 116,785 | 110,412 | - | - |
| Change | - | -29.77% | -49.28% | -40.28% | 72.37% | -5.46% | - | - |
| Enterprise Value (EV) 1 | 312,249 | 220,078 | 108,009 | 62,506 | 105,088 | 99,134 | 95,982 | 89,880 |
| Change | - | -29.52% | -50.92% | -42.13% | 68.13% | -5.67% | -3.18% | -6.36% |
| P/E Ratio | 97.9x | 52.4x | 34.9x | 21.2x | 24.4x | 20.1x | 16.7x | 13.8x |
| PBR | 10.3x | 6.38x | 2.9x | 1.67x | 2.2x | 1.98x | 1.74x | 1.52x |
| PEG | - | 1.7x | -1.5x | 16.32x | 0.5x | 1.4x | 0.8x | 0.7x |
| Capitalization / Revenue | 31x | 14.7x | 6.66x | 3.63x | 5.36x | 4.38x | 3.73x | 3.21x |
| EV / Revenue | 30.3x | 14.4x | 6.34x | 3.35x | 4.82x | 3.93x | 3.24x | 2.61x |
| EV / EBITDA | 68x | 32.1x | 15.4x | 7.81x | 10.7x | 10.2x | 8.33x | 6.65x |
| EV / EBIT | 93.9x | 47.8x | 25.4x | 13.2x | 15.3x | 12.3x | 9.87x | 7.79x |
| EV / FCF | -101x | -674x | 174x | 48.5x | 45.7x | 45.9x | 27.8x | 15.3x |
| FCF Yield | -0.99% | -0.15% | 0.58% | 2.06% | 2.19% | 2.18% | 3.59% | 6.52% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.77 | 1.01 | 0.77 | 0.78 | 1.16 | 1.326 | 1.601 | 1.93 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10,290 | 15,269 | 17,034 | 18,675 | 21,790 | 25,222 | 29,593 | 34,421 |
| EBITDA 1 | 4,590 | 6,857 | 6,993 | 7,999 | 9,820 | 9,711 | 11,528 | 13,525 |
| EBIT 1 | 3,327 | 4,609 | 4,253 | 4,737 | 6,852 | 8,074 | 9,721 | 11,536 |
| Net income 1 | 3,388 | 4,420 | 3,400 | 3,356 | 4,908 | 5,497 | 6,653 | 7,918 |
| Net Debt 1 | -6,241 | -3,612 | -5,448 | -5,246 | -11,697 | -11,278 | -14,431 | -20,532 |
| Reference price 2 | 75.40 | 52.94 | 26.87 | 16.50 | 28.25 | 26.71 | 26.71 | 26.71 |
| Nbr of stocks (in thousands) | 4,224,123 | 4,225,262 | 4,222,732 | 4,105,938 | 4,133,579 | 4,133,541 | - | - |
| Announcement Date | 3/22/22 | 3/22/23 | 3/26/24 | 3/25/25 | 3/24/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E Ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.25x | 3.95x | 10.26x | -.--% | 16.4B | |
| 33.17x | 8.64x | 26.13x | 0.05% | 56.42B | |
| 16.69x | 5.03x | 10.91x | 1.8% | 44.54B | |
| -17.8x | 4.17x | -7.3x | -.--% | 22.9B | |
| -36.36x | 12.23x | -35.67x | -.--% | 21.21B | |
| 21.44x | 4.3x | 14.23x | -.--% | 15.4B | |
| 16.8x | 4.85x | 11.36x | -.--% | 13.35B | |
| -433.48x | 29.5x | -3289.39x | -.--% | 12.36B | |
| 36.9x | 14.16x | 41.61x | 0.18% | 11.15B | |
| -69.99x | 7.06x | -63.29x | -.--% | 11.08B | |
| Average | -41.24x | 9.39x | -328.11x | 0.2% | 22.48B | |
| Weighted average by Cap. | -15.11x | 8.29x | -174.84x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 2269 Stock
- Valuation WuXi Biologics (Cayman) Inc.
Select your edition
All financial news and data tailored to specific country editions
